skip to Main Content

Evonik and JeNaCell intensify their coöperation

  • 2016
  • Evonik Chair­man Klaus Engel vis­its BioIn­stru­men­ta­tion Cen­ter in Jena for on-site brief­ing on pro­duc­tion expansion
  • Engel: “Out­stand­ing exam­ple of indus­trial biotechnology’s potential.”
  • JeNa­Cell prepar­ing mar­ket launch of a new prod­uct line in the area of dermatology

Essen. Inno­va­tions and busi­ness oppor­tu­ni­ties were the focus of a recent visit by Evonik Chair­man Klaus Engel at JeNa­Cell. “The com­pany is an out­stand­ing exam­ple of indus­trial biotechnology’s poten­tial. It is impres­sive to wit­ness how sci­en­tific research is turned into mar­ket-ready prod­ucts here. This is true entre­pre­neur­ial spirit,” said Engel dur­ing a tour of the pro­duc­tion facil­i­ties. At the BioIn­stru­men­ta­tion Cen­ter in Jena, Engel was briefed on the company’s expand­ing pro­duc­tion and the mar­ket launch of new prod­ucts. JeNa­Cell is a spin­off ven­ture of Friedrich Schiller Uni­ver­sity.  As part of its ven­ture cap­i­tal activ­i­ties, in sum­mer last year Evonik acquired a minor­ity share in the com­pany, which was founded in 2012 by two chemists, Nadine Heßler and Dana Kralisch.

Dur­ing Dr. Engel’s visit, Nadine Heßler, the exec­u­tive man­ager of JeNa­Cell, empha­sized: “Evonik is a strong strate­gic investor who sup­ports us in many areas. We not only ben­e­fit from our partner’s know-how as our com­pany con­tin­ues to grow, but the part­ner­ship also offers the option of joint prod­uct developments.”

For Evonik, the col­lab­o­ra­tion with JeNa­Cell offers access to an inno­v­a­tive mate­r­ial plat­form. Nanocel­lu­lose can serve as a car­rier sys­tem for cos­metic and med­ical active ingre­di­ents. Evonik and JeNa­Cell have already ini­ti­ated the first joint projects in this area. In addi­tion, JeNa­Cell is work­ing with process tech­nol­ogy engi­neers from Evonik to look into ways of fur­ther expand­ing the scale of its nanocel­lu­lose pro­duc­tion process.

JeNa­Cell is cur­rently prepar­ing the mar­ket launch of a new prod­uct line in the area of der­ma­tol­ogy. It is due to be launched at the end of the first quar­ter of 2016. The prod­ucts are used to aid ther­a­peu­tic mea­sures in med­ical cos­me­tol­ogy, laser treat­ments, and skin sen­si­tiv­i­ties or to sup­ple­ment aes­thetic pro­ce­dures such as exfo­li­a­tion. As doc­u­mented by cur­rent stud­ies, they have a long-last­ing mois­tur­iz­ing, cool­ing, and sooth­ing effect on the skin and sup­port the nat­ural regen­er­a­tion of sen­si­tive skin.

JeNa­Cell is a spe­cial­ist in gen­er­at­ing nanocel­lu­lose using biotech­nol­ogy meth­ods and has a unique pro­duc­tion process in this field. Among other appli­ca­tions, the mate­r­ial enables the improved treat­ment of burn injuries and chronic wounds. It feels pleas­antly cool on the skin, reg­u­lates the mois­ture level of wounds, and can be removed painlessly.

Evonik intends to invest some €100 mil­lion in promis­ing start-ups with inno­v­a­tive tech­nolo­gies and in lead­ing spe­cial­ized ven­ture cap­i­tal funds as part of its ven­ture cap­i­tal activ­i­ties. Regional focus areas include Europe, the U.S., and Asia. Evonik cur­rently holds shares in eight start-ups and four funds. For more infor­ma­tion, visit

Back To Top
×Close search